ORKA Stock Overview
A biotechnology company, develops novel biologics for the treatment of chronic skin diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Oruka Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$26.00 |
| 52 Week High | US$31.13 |
| 52 Week Low | US$23.98 |
| Beta | 0 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -9.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| ORKA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.0% | 1.3% | 0.3% |
| 1Y | n/a | 16.5% | 21.7% |
Return vs Industry: Insufficient data to determine how ORKA performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how ORKA performed against the US Market.
Price Volatility
| ORKA volatility | |
|---|---|
| ORKA Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ORKA has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ORKA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Lawrence Klein | orukatx.com |
Oruka Therapeutics, Inc., a biotechnology company, develops novel biologics for the treatment of chronic skin diseases. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23 (IL-23p19); and ORKA-002 that targets interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of psoriasis psoriatic arthritis, and other inflammatory diseases. The company is based in Waltham, Massachusetts.
Oruka Therapeutics, Inc. Fundamentals Summary
| ORKA fundamental statistics | |
|---|---|
| Market cap | US$764.36m |
| Earnings (TTM) | US$0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs ORKA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ORKA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$0 |
| Earnings | US$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did ORKA perform over the long term?
See historical performance and comparison